Activity of enoxaparin sodium in tuberculin syringes for 10 days

American Journal of Health-System Pharmacy

Volumn 55, Issue 12, 1998, Pages 1296-1298

  Charland, Scott L ^a,b,d   Davis, Diane D ^c   Tillman, Donald J ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAISER PERMANENTE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; PYROGEN;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PACKAGING; DRUG SAFETY; DRUG STERILITY; DRUG STORAGE; LIMULUS LYSATE TEST; PH; PRIORITY JOURNAL; SYRINGE; VEIN THROMBOSIS;

EID: 0032526712     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.12.1296     Document Type: Article

References (11)

1. Lovenox package insert. Collegeville, PA: Rhône-Poulenc Rorer; 1997 Mar.
2. Leizorovicz A. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: an updated meta-analysis. Drugs. 1996; 52(suppl 7):30-7.
3. Levine M, Gent M, Hirsch J et al. A comparison of low-molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-venous thrombosis. N Engl J Med. 1996; 334:667-81.
4. Charland SL, Tillman D, Davis DD et al. The use of a low-molecular weight heparin in the outpatient treatment of venous thrombosis. Pharmacotherapy. 1997; 17:183. Abstract.
5. Koopman MMW, Prandoni P, Piovella F et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular weight heparin administered at home. N Engl J Med. 1996; 334:682-7.
6. Teien AN, Lie M, Abildgaard U. Assay of heparin in plasma using a chromogenic substrate. Thromb Res. 1976; 8:413-6.
7. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increase sensitivity by adding purified antithrombin III. Thromb Res. 1977; 10:399-410.
8. Enoxaparin sodium. Pharm Forum. 1996; 22:3031-8.
9. Cooper JF, Levin J, Wagner HN. Quantitative comparison of in vitro and in vivo methods for the detection of endotoxin. J Lab Clin Med. 1971; 78:138-48.
10. Mewborn AL, Kessler JM, Joyner KA. Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours. Am J Health-Syst Pharm. 1996; 53:167-9.
11. Anderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Wochester DVT study. Arch Intern Med. 1991; 151:933-8.